Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...
BMO analysts say Eli Lilly is well-positioned to maintain its lead in the ballooning weight loss space, predicting “strengthening leadership in obesity and beyond” as portfolios expand and patient ...
For years, employers have sought to streamline their relationships with drugmakers to lower costs. But until recently, there ...
Agency officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs used ...
Adults with type 1 diabetes who used a GLP-1 receptor agonist or other incretin-based drug had lower risk for all-cause ...
Investor's Business Daily on MSN
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.
After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...
After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback